Loading clinical trials...
Loading clinical trials...
Active Control of Prostatic Cancer With Criteria of Latence. Impact on Specific 10 Years Survival.
This study concern a prospective cohort pf patients with latent prostate cancer. We study the specific survival at 10 years of patients who accept an active control.Patients inclusion are realized in 2 stages: * patient with inclusion criteria (PSA \< 10 ng/ml, clinical stage T1c or T2a, Gleason \< or = 6) are registered if they accept a second prostate biopsy in a 3 months delay * after analyse of second biopsy in central laboratory and confirmation of latent prostate biopsy, patients are included if they accept active control Included patients will have 1 biopsy by years the first two years and then 1 biopsy each 2 years during 8 years. If progression of cancer happens during the 10 years control, active control will be stopped and patient will be treated by surgery and chemotherapy.
This study concern the active control during 10 years of patient with latent prostate cancer who accept not be treated immediately.
Age
18 - 74 years
Sex
MALE
Healthy Volunteers
No
R Azzouzi
Angers, France
Jean-Louis DAVIN
Avignon, France
Henri BENSADOUN
Caen, France
SALOMON
Créteil, France
René GASCHIGNARD
La Roche-sur-Yon, France
RUFFION
Lyon, France
Eric LECHEVALLIER
Marseille, France
P. ROSSI
Marseille, France
Xavier REBILLARD
Montpellier, France
RIGAUD Jérôme
Nantes, France
Start Date
December 1, 2007
Primary Completion Date
December 1, 2013
Completion Date
December 1, 2013
Last Updated
June 4, 2015
100
ACTUAL participants
prostate biopsy
PROCEDURE
Lead Sponsor
Clinique Mutualiste Chirurgicale de la Loire
NCT05691465
NCT06842498
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04550494